Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-11-29

Clinical Trial Update: Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of lornoxicam in mild to moderate probable Alzheimer’s disease was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lornoxicam (lornoxicam)

Snippet

Sponsor: JSW Lifesciences | Conditions: Alzheimer´s Disease | Phase 2 | Status: TERMINATED | Results posted: 2012-11-29